The influence of selected factors on the risk of myocardial infarction
DOI:
https://doi.org/10.12923/j.2084-980X/25.4/a.16Keywords:
myocardial infarction, age, sex, duration of coronary artery disease, smoking, LDL cholesterol levelAbstract
The most important risk factors for heart attack are considered to be: lifestyle, smoking, high-calorie diet rich in animal fats, physiological and biochemical factors, elevated levels of cholesterol - especially LDL cholesterol, elevated concentration of triglycerides, hyperglycemia or diabetes, increased levels of homocysteine, elevated thrombotic factors. The aim of the study was to analyze the influence of selected factors on the risk of myocardial infarction. The study was conducted among patients with diagnosed coronary artery disease who reported to the family doctor for a check. The effect of selected variables: age, sex, duration of coronary artery disease, smoking, and LDL cholesterol on the risk of myocardial infarction was studied. The results were statistically analyzed. It was found that the incidence of myocardial infarction is higher in men than in women, especially of premenopausal age. In the age group 35-44 years, the risk of the disease in men is almost nine times higher than in women. The risk of heart attack increases with age in both men and women. Among smokers heart attacks are observed significantly more frequently, and the risk of heart attack in this group is more than 2-fold higher than in non-smokers. The longer the duration of coronary artery disease, the risk of myocardial infarction increases. In patients with elevated LDL cholesterol the risk of heart attack is more than 3-fold higher than in those with normal levels.
References
1. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation, 104, 2996, 2001.
2. Baghaei A. et al.: How effective are strategies for non-communicable disease prevention and control in a high risk population in a developing country? Isfahan Healthy Heart Programme. Arch. Med. Sci., 6, 24, 2010.
3. Barnoya J. and Glantz S.A.: Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation, 111, 2684, 2005.
4. Bolego C. et al.: Smoking and gender. Cardiovasc. Res., 53, 568, 2002.
5. Braunwald E. et al.: Braunwald’s Heart Disease. A Textbook of cardiovascular medicine. 8th ed. Saunders, 2008.
6. Burr M.L. et al.: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 2, 757, 1989.
7. Cieśliński A. (editor): Ogólnopolski Program Prewencji Choroby Wieńcowej Polscreen. Poznań: Termedia, 2006.
8. Conroy R. et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J., 24, 987, 2003.
9. De Backer G. et al.: Third Joint Task Force of European and other Societies on Cardiovascular Diseases Prevention in Clinical Practice. European guidelines on cardiovascular diseases prevention in clinical practice. Eur. Heart J., 24, 1601, 2003.
10. Graham I. et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur. Heart. J., 28, 2375, 2007.
11. Fox K. et al.: Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341, 2006.
12. He J. et al.: Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N. Eng. J. Med., 340, 920, 1999.
13. http://chorujena.pl/Choroba/668-Choroba_niedokrwienna_serca
14. Hu F.B. et al.: Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N. Engl. J. Med,. 343, 530, 2000.
15. Janion‑Sadowska A. et al.: Differences in presentation, treatment, and prognosis in elderly patients with non ST segment elevation myocardial infarction. Pol. Arch. Med. Wewn., 122, 253, 2012.
16. Josan K. et al.: The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMJ, 178, 576, 2008.
17. Kawecka-Jaszcz K. and Jankowski P.: Ocena globalnego ryzyka sercowo-naczyniowego. In: Postępowanie z chorym o dużym ryzyku sercowo-naczyniowym. Januszewicz A., Naruszewicz M. and Rużyłło W. (editors). Kraków: Medycyna Praktyczna, p. 33, 2005.
18. Kawecka-Jaszcz K. and Jankowski P.: Wtórna prewencja choroby niedokrwiennej serca. Nowa Klinika, 8, 1357, 2001.
19. Khot U.N. et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 290, 898, 2003.
20. Kowalski J. et al.: Estimation of cardiovascular complications and death risk in subjects with metabolic syndrome. Arch. Med. Sci., 2, 252, 2006.
21. Lai H.M. et al.: The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. Arch. Med. Sci., 8, 53, 2012.
22. Law M.R., Wald N.J. and Thompson S.G.: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ, 308, 362, 1994.
23. Marchioni R. et al.: Early protection against sudden death by omega-3 polyunsaturated fatty acids after myocardial infarction. Time course analysis of the results of the (GISSI)-Prevenzione. Circulation, 105, 1897, 2002.
24. Mercando A.D. et al.: Reduction in atherosclerotic events through use of aggressive risk factor reduction medications: a retrospective study in an outpatient cardiology practice. Arch. Med. Sci., 8, 57, 2012.
25. Narkiewicz K.: Ponure fakty o paleniu papierosów. Zdrowie.med.pl 2012
26. Ogólnopolskie i regionalne rozpowszechnienie głównych czynników ryzyka układu sercowo-naczyniowego. Wyniki ogólnopolskiego badania stanu zdrowia ludności (WOBASZ). Kard. Pol., (Suppl.4) 63; 614, 2005.
27. Piwowarska W.: Choroba niedokrwienna serca. Część I – objawy ostrzegające o chorobie. Liga Zdrowego Serca, 2012.
28. Piwowarska W.: Choroba niedokrwienna serca. Część II – w jaki sposób lekarz rozpoznaje i leczy chorobę niedokrwienną serca. Liga Zdrowego Serca, 2012.
29. Powell B.D. et al.: Association of body mass index with outcome after percutaneous coronary intervention. Am. J. Cardiol., 91, 472, 2003.
30. Sadowski M., Gąsior M. and Poloński L. Zawał serca z uniesieniem odcinka ST (STEMI) u kobiet. Polskie kobiety na tle innych populacji kobiet. Przewodnik Lekarza, 4, 98, 2010.
31. Scientific Position. Risk Factors and Coronary Heart Disease. AHA Scientific Statements on Prevention of Coronary Heart Disease and Stroke, 2007.
32. Shaw L.J., Bugiardini R. and Bairey Merz CN.: Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol., 54, 1561, 2009.
33. Shaw L.J. et al.: National Heart, Lung and Blood Institute; American College of Cardiology Foundation. Women’s Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 5: Gender-related risk factors for ischemic heart disease. Circulation, 109: e56, 2004.
34. Shaw L.J. et a.: WISE Investigators. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J. Am. Coll. Cardiol., 47 (3 suppl): S4, 2006.
35. Szczęch R., Grodzka T. and Narkiewicz K.: Edukacja chorych z nadciśnieniem tętniczym. Promocja Zdr. Nauki Społ. Med., 8, 7, 2001.
36. Tonstad S. and Johnston J.A.: Cardiovascular risk associated with smoking: a review for clinicians. Eur. J. Cardiovasc. Prev. Rehabil., 13, 507, 2006.
37. Vasan R. et al.: Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann. Intern. Med., 142, 393, 2005.
38. Wood D., Kotseva K. and Connolly S.: Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlle. Lancet, 371,1999, 2008.
39. Wood D.: Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ, 320, 705, 2000.
40. www.rejestrozw.republika.pl.
41. Yusuf S. et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364, 937, 2004.
42. Zdrojewski T. et al.: Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. Kard. Pol., 61(Suppl.4), 1, 2004.
Downloads
Published
Issue
Section
License
Copyright (c) 2012 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
